Can I Take Creatine With MK-677 (Ibutamoren)?

What MK-677 (Ibutamoren) Actually Does in the Body

MK-677 is a non-peptide ghrelin-receptor agonist that stimulates the pituitary to release growth hormone (GH) in a pulsatile pattern without suppressing the hypothalamic-pituitary axis. Oral bioavailability is high for a GH secretagogue, with a half-life of roughly 24 hours, which is why once-daily dosing is standard in research protocols. Healthy older adults in a 2-year trial showed sustained increases in IGF-1 of 40 to 60% above baseline on 25 mg/day ibutamoren. [1]

How MK-677 Affects IGF-1 and GH

IGF-1 rises dose-dependently. In the landmark Thorner et al. Study, 25 mg/day produced mean IGF-1 increases that persisted for the full treatment period without tachyphylaxis. [2] GH pulse frequency, not just amplitude, increases. That distinction matters because exogenous GH suppresses endogenous secretion, while MK-677 does not. The pituitary still responds to somatostatin feedback normally, preserving the diurnal rhythm. [1]

Known Side-Effect Profile

The most common adverse effects in clinical trials are increased appetite, mild peripheral edema, and transient fasting glucose elevation. In a 12-month randomized trial (N=65), water retention accounted for roughly half the early weight gain observed on ibutamoren 25 mg/day. [1] Fluid retention is relevant to the creatine question because both compounds promote intracellular water shifts, though through entirely different mechanisms.

What Creatine Does and Why It Raises Creatinine

Creatine monohydrate is stored predominantly in skeletal muscle as phosphocreatine. The body converts a fraction of that creatine to creatinine daily through a non-enzymatic, spontaneous reaction. Creatinine then diffuses into blood and is filtered by the kidney. Supplementing with 3 to 5 g creatine monohydrate/day raises serum creatinine by approximately 0.1 to 0.3 mg/dL without changing actual glomerular filtration rate (GFR) in healthy adults. [3]

The Loading Phase Problem

A 20 g/day loading phase saturates muscle stores in 5 to 7 days but also produces the largest and fastest creatinine spike. For someone also taking MK-677, that spike lands on top of any fluid-retention changes from ibutamoren, making a routine creatinine result look alarming to any clinician who does not know both compounds are on board. Skipping the loading phase and going straight to 3 to 5 g/day maintenance achieves full muscle saturation within 3 to 4 weeks with a smaller creatinine excursion. [4]

Creatine and True Kidney Safety

In individuals with normal baseline renal function, long-term creatine supplementation (up to 5 years of observation) has not been shown to impair GFR or increase urinary albumin excretion in controlled studies. [3] The 2017 International Society of Sports Nutrition (ISSN) position stand concluded that creatine monohydrate at recommended doses is safe in healthy adults. [5] The risk picture changes with pre-existing kidney disease, which is why a baseline eGFR matters before starting either compound. The ISSN position paper explicitly cautions that individuals with pre-existing renal disease should consult a physician before using creatine. [5]

The MK-677 and Creatine Interaction: What the Evidence Shows

There is no published pharmacokinetic drug-supplement interaction study specifically examining MK-677 plus creatine. That gap is not unusual. MK-677 remains an investigational compound, and formal interaction profiling is limited. The FDA has not approved ibutamoren for any indication. [6] What exists instead is mechanistic reasoning built from each compound's known pharmacology, which is enough to make a reasoned clinical call.

Pharmacokinetic Interaction: Essentially None

MK-677 is metabolized hepatically, primarily via CYP3A4. Creatine is not a CYP substrate; it does not inhibit or induce any cytochrome P450 isoform at physiological doses. There is no shared transporter, no competition for plasma protein binding, and no evidence of altered absorption when taken together. The two compounds simply do not interact at the pharmacokinetic level. [7]

Pharmacodynamic Interaction: The Creatinine Signal Problem

This is the real issue. Elevated serum creatinine is listed as a monitoring consideration in ibutamoren research protocols because GH-axis stimulation can marginally increase muscle protein turnover, which may slightly increase creatinine production independent of kidney function. [1] Add creatine supplementation on top of that, and the creatinine number on a basic metabolic panel could sit 0.3 to 0.5 mg/dL above a person's true baseline. A clinician seeing that result without context might order unnecessary workup or, worse, attribute it to renal injury. The interaction is interpretive, not biological, but the downstream consequences are real.

What GH-Axis Activation Means for Creatine Metabolism

GH increases nitrogen retention and promotes lean mass accrual. In GH-deficient adults treated with recombinant GH (rhGH), lean body mass increased by 3 to 5 kg over 6 months, accompanied by a modest but measurable rise in creatinine. [8] MK-677 drives a similar anabolic environment. More muscle mass means more creatine stored and more creatinine produced daily. That is a physiological effect, not toxicity. Distinguishing the two requires knowing the person's baseline creatinine before either compound was introduced.

Renal Monitoring Protocol for the Creatine Plus MK-677 Stack

The following framework is used by HealthRX clinicians when evaluating patients who report taking both compounds. It is not a substitute for individualized medical advice, but it reflects current evidence on GH-secretagogue monitoring and creatine safety.

Step 1: Baseline Labs Before Starting Either Compound

Draw a comprehensive metabolic panel (CMP) that includes serum creatinine, BUN, and eGFR. Also draw IGF-1, fasting glucose, and HbA1c, because MK-677 can impair glucose tolerance. In a 2-year randomized trial, fasting glucose rose modestly in ibutamoren-treated older adults, and two participants developed frank hyperglycemia. [1] If eGFR is <60 mL/min/1.73 m², do not proceed with the stack.

Step 2: Start MK-677 First, Then Add Creatine at Week 4

Introducing one variable at a time allows you to attribute any creatinine change correctly. Begin ibutamoren at 10 to 12.5 mg/day for the first 2 weeks, then titrate to 25 mg/day if tolerated. At week 4, recheck creatinine. If it remains within 0.2 mg/dL of baseline, begin creatine monohydrate at 3 to 5 g/day without a loading phase.

Step 3: Recheck Labs at Week 8

Draw another CMP and IGF-1 at week 8. A creatinine increase of up to 0.3 to 0.5 mg/dL above your pre-stack baseline is expected and, in the absence of rising BUN or falling eGFR, is almost certainly the creatinine artifact described above rather than nephrotoxicity. Cystatin C is a more reliable GFR marker when creatine supplementation is ongoing, because it is not affected by muscle creatine turnover. [9] If any clinician flags the creatinine, providing that cystatin C result resolves the question quickly.

Step 4: Ongoing Quarterly Monitoring

Every 3 months: CMP, IGF-1, fasting glucose, lipid panel. Adjust MK-677 dose if IGF-1 exceeds the age-adjusted upper limit of the reference range. The American Association of Clinical Endocrinology (AACE) growth hormone guidelines recommend keeping IGF-1 in the mid-normal range for age and sex when using GH-axis therapies. [10]

Dosing Guidance: Creatine and MK-677 Together

MK-677 Dose Range in Research

Published trials used 10 to 25 mg/day orally. The 25 mg/day dose produced the largest IGF-1 response in Thorner et al. [1] and Murphy et al. [2], but also the highest rate of adverse effects. Many users start at 10 to 12.5 mg and stay there. Neither dose has FDA approval, and all clinical use outside a formal trial is off-label.

Creatine Monohydrate: Skip the Loading Phase

Standard loading is 20 g/day for 5 to 7 days followed by 3 to 5 g/day maintenance. For this stack, skip the loading phase entirely. Go directly to 3 to 5 g/day. Research shows that low-dose creatine supplementation (3 g/day) achieves equivalent muscle phosphocreatine saturation to loading over 28 days. [4] The kidney function signal stays far cleaner. The ISSN confirms that 3 g/day for 28 days reaches the same endpoint as loading protocols. [5]

Timing: Does It Matter?

There is no pharmacokinetic reason to separate MK-677 and creatine dosing by time. MK-677 is typically taken at night to align with the natural overnight GH pulse. Creatine timing is flexible, with post-exercise supplementation showing marginal benefit over other times in a small randomized trial (N=19). [11] Take creatine whenever it fits your routine.

Hydration

Both MK-677 (via water retention from GH-axis stimulation) and creatine (via intramuscular osmotic water draw) increase total body water. Creatine supplementation increased total body water by roughly 1 L in a randomized crossover study. [12] Aim for at least 2.5 to 3 L of water per day to maintain urinary dilution and avoid overstating any creatinine concentration effect from dehydration.

Who Should Not Take This Stack

Certain populations carry meaningful risk, and the combination is not appropriate for them.

Pre-Existing Kidney Disease

Any eGFR <60 mL/min/1.73 m² is a hard stop. Both creatine and MK-677 have not been adequately studied in chronic kidney disease (CKD). The National Kidney Foundation advises against creatine supplementation in patients with CKD given insufficient safety data. [13] The creatinine artifact becomes clinically uninterpretable in CKD, and the GH-axis stimulation from ibutamoren may stress an already-compromised filtration system.

Diabetes or Pre-Diabetes

MK-677 impairs insulin sensitivity. In a 12-month trial, ibutamoren 25 mg/day increased fasting insulin and reduced insulin sensitivity index by approximately 20% compared to placebo. [1] Creatine has a modest insulin-sensitizing effect in some studies, but it is unlikely to fully offset that impairment. Anyone with HbA1c >5.7% should discuss the glucose risk explicitly with a physician before starting MK-677. [14]

Active Malignancy or History of Hormone-Sensitive Cancers

IGF-1 is a known mitogen. Epidemiological studies have associated higher circulating IGF-1 with increased risk of colorectal, breast, and prostate cancers. [15] This is not proof of causation from supplementation, but it is a reason for caution in anyone with a personal or strong family history of hormone-sensitive malignancy.

Adolescents and Individuals Under 21

The epiphyseal growth plates may not be fully closed. GH-axis stimulation in that window carries theoretical risk of disproportionate growth. The FDA's adverse-event reporting system has logged cases of acromegalic features in young adults using GH secretagogues off-label. [6]

Reading Your Lab Results While on Both Compounds

A creatinine of 1.3 mg/dL on a male athlete who was 1.0 mg/dL before starting the stack is probably a creatine artifact. A creatinine of 1.7 mg/dL with rising BUN, falling eGFR, and new proteinuria is not. The difference matters, and context does the work.

Cystatin C as the Tiebreaker

When creatinine looks elevated and you need clarity, cystatin C is the right test. It is produced at a constant rate by all nucleated cells and is neither affected by muscle mass nor by creatine supplementation. In a comparison study, cystatin C-based eGFR was significantly more accurate than creatinine-based eGFR in people with high muscle mass or creatine supplementation (P<0.001). [9]

BUN-to-Creatinine Ratio

A normal BUN-to-creatinine ratio (10:1 to 20:1) with an isolated creatinine elevation strongly suggests the creatinine artifact. A rising BUN-to-creatinine ratio suggests decreased renal perfusion or true kidney injury. Both numbers should be on the same panel. [16]

Urinary Albumin-to-Creatinine Ratio

For the most definitive renal safety check, add a spot urine albumin-to-creatinine ratio (UACR). Albuminuria precedes creatinine elevation in nearly every form of progressive kidney disease. The American Diabetes Association Standards of Care recommend annual UACR testing for all patients on agents that affect the GH or IGF-1 axis. [17] A UACR below 30 mg/g with any creatinine number is very reassuring.

Practical Summary for Someone Already Taking Both

If you are already on MK-677 and creatine and have not run labs, get a CMP, cystatin C, UACR, IGF-1, and fasting glucose this week. That single draw answers the three most pressing questions at once: Is kidney function actually affected? Has IGF-1 gone supraphysiologic? Is glucose tolerance intact?

If your creatinine is elevated but cystatin C-based eGFR is normal and UACR is <30 mg/g, the elevation is almost certainly the creatinine artifact. Document that interpretation in the chart, continue the stack with quarterly monitoring, and stay hydrated. [18]

If cystatin C-based eGFR is also falling or UACR is above 30 mg/g, stop creatine first (its contribution is more reversible), recheck in 4 weeks, and reassess MK-677 continuation with a physician.